Evidence map›Paper›PMID 40426019›Full record

ArticleOncoimmunology2025

Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody.

Willemijn van der Wulp, Dennis F G Remst, Carli S Koster, Anne K Wouters, Maaike E Ressing, Janine Schuurman, Sander I van Kasteren, Boris Bleijlevens, Rob C Hoeben, Lars Guelen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Willemijn van der WulpDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Dennis F G RemstDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Carli S KosterDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Anne K WoutersDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Maaike E RessingDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Janine SchuurmanGenmab, Utrecht, The Netherlands.
Sander I van KasterenDivision of Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
Boris BleijlevensGenmab, Utrecht, The Netherlands.
Rob C HoebenDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Lars GuelenGenmab, Utrecht, The Netherlands.
Mirjam H M HeemskerkDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-epitope conjugates (AECs) proved to be a promising new therapeutic strategy to redirect virus-specific CD8

Indexed as

Antibodies, BispecificEpitopes, T-LymphocyteAnimalsCD8-Positive T-LymphocytesCell Line, TumorCytomegalovirusFemaleHerpesvirus 4, HumanHumansMiceNeoplasmsAntibodies, BispecificEpitopes, T-LymphocyteAntibody-epitope conjugates (AECs)bispecific-AECsimmunotherapyredirecting T-cellstandem-AECsvirus-specific T-cells

Identifiers

PMID40426019
PMCPMC12118402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.